New mRNA flu shot enters human testing
NCT ID NCT05755620
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a single dose of a new mRNA flu vaccine (VRC H1ssF-3928) in 50 healthy adults aged 18 to 49. The vaccine aims to teach the body to fight a stable part of the flu virus. Researchers are checking for side effects and measuring immune responses, comparing them to a standard flu shot.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA flu vaccine (VRC H1ssF-3928)
- What this could lead to
- If successful, this could pave the way for a more effective flu vaccine that targets a stable part of the virus, potentially offering broader protection.
- What could go wrong
- This is a very early Phase 1 trial with only 50 people, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts